Mesoblast (MESO) Earnings Date & Reports
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions... Show more
MESO is expected to report earnings to fall 366.67% to 7 cents per share on November 25
Mesoblast Limited (MESO) H1 FY2026 Earnings Recap: Ryoncil Launch Fuels Revenue Surge
Key Takeaways
- Mesoblast reported total revenue of $51.3 million for H1 FY2026 (half-year ended December 31, 2025), up from $3.2 million a year ago, driven by $48.7 million in net Ryoncil product sales.
- Net loss improved to $40.2 million from $47.9 million year-over-year, with loss per share at 3.11 cents versus 4.20 cents; excluding prior-year inventory reversal, improvement was $30.7 million.
- Ryoncil achieved 93% gross margin (gross profit excluding amortization: $44.2 million), with 49 transplant centers onboarded and payer coverage for 280 million U.S. lives.
- Cash balance stood at $130 million at period-end, bolstered by a new $125 million non-dilutive credit facility ($75 million drawn).
- Company reaffirmed FY2026 Ryoncil net revenue guidance of $110–120 million and expects reduced cash burn in H2 FY2026.
- Pipeline advances include Phase 3 enrollment completion for chronic low back pain by March/April 2026 and BLA filing for heart failure next quarter.
Earnings Context and Why It Matters
Mesoblast Limited (MESO), a leader in allogeneic cellular medicines, marked a pivotal shift with the U.S. commercial launch of Ryoncil (remestemcel-L-rknd), its FDA-approved therapy for pediatric steroid-refractory acute graft-versus-host disease (SR-aGvHD). This H1 FY2026 report (ended December 31, 2025) underscores the transition from clinical-stage biotech to revenue-generating entity amid a challenging funding environment for cell therapies. Strong early Ryoncil uptake validates Mesoblast's mesenchymal stromal cell platform, while reaffirmed full-year guidance signals commercialization momentum. For investors, it highlights cash sustainability, pipeline potential in adult SR-aGvHD, chronic low back pain, and heart failure, against ongoing losses typical for growth biotechs.
Mesoblast's official H1 FY2026 results showed total revenue of $51.3 million, surpassing prior-year $3.2 million, primarily from $48.7 million net Ryoncil sales (gross $57.0 million). Royalty revenue was $2.7 million. Cost of revenues was $7.6 million, yielding 93% gross margin on Ryoncil (excluding $3.1 million amortization). R&D expenses rose to $46.2 million from $5.1 million, reflecting pipeline investments; SG&A increased to $28.5 million due to commercialization. Net loss narrowed to $40.2 million ($0.0311 per share) from $47.9 million ($0.0420 per share).
Revenue beat low prior-year figures and some estimates (e.g., $22.92M consensus per Investing.com), but missed higher forecasts around $53M. EPS improved but trailed optimistic expectations like -$0.007. Key metrics exceeded: 84% patients completed 28-day regimen alive; 49 centers onboarded vs. 64 target. Cash was $130 million; net operating cash use $30.3 million. Guidance: Ryoncil FY2026 net sales $110-120M, H2 cash burn decline.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions in dynamic markets like biotech. Explore the AI Screener today to uncover potential opportunities in regenerative medicine and beyond.
Market Reaction and Investor Sentiment
Post-earnings on February 26-27, 2026, MESO shares declined about 6.3% initially, closing February 27 at around $15.85 from $16.92 pre-release, reflecting mixed sentiment despite revenue beat on low base and strong margins. Some sources noted 8-9% drop amid broader sell-off, as higher expenses and EPS miss weighed on views. Sentiment remains cautiously optimistic on Ryoncil traction and guidance, tempered by path to profitability.
Forward Outlook and Key Factors to Monitor
Mesoblast's reaffirmed FY2026 Ryoncil net revenue guidance of $110-120 million positions the product as a cash engine, with H2 expected to show reduced operating cash burn versus H1's $30.3 million, supported by quarterly revenue ramps and $130 million cash plus $50 million credit tranche availability.
Pipeline catalysts loom large. Enrollment in the confirmatory Phase 3 for rexlemestrocel-L in chronic discogenic low back pain (CLBP, a blockbuster indication) targets completion by March/April 2026, paving for 2027 BLA. BLA for rexlemestrocel-L in end-stage heart failure with LVADs (left ventricular assist devices) eyes filing next quarter, leveraging new data on reduced hospitalizations without need for confirmatory trial if approved. Lifecycle extension for Ryoncil in adult SR-aGvHD Phase 3 protocol advances to IRB submission in March 2026.
Monitor payer expansions (already 280 million lives covered), transplant center onboarding (target 64), real-world outcomes, manufacturing scale-up for second-gen products, and debt repayment progress on the royalty facility by mid-2026. Industry dynamics in cell therapy approvals and reimbursement will shape trajectory.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
a company, which engages in the development and commercialization of biological products
Industry Biotechnology